Health Trials

Relapsed/Refractory Hematological Malignancies

3

Review clinical trials related to Relapsed/Refractory Hematological Malignancies. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.

Participants needed: 180
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Ascentage Pharma Group Inc.Updated: Feb 20, 2026Locations: 2
Eligibility criteria

Eastern Cooperative Oncology Group (ECOG) status ≤ 1 in Part 1 (dose escalation)... [+4]

Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immuno... [+16]

Read more
Status: Not yet recruiting

A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies

This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary antitumor activity of QLS2313 as a monotherapy in patients with relapsed/refractory hematological malignancies.

Participants needed: 124
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Qilu Pharmaceutical Co., Ltd.Updated: Dec 19, 2025Locations: 1
Eligibility criteria

Males or females aged ≥ 18 years； [+4]

Previous treatment with a CD79b/CD3/CD20 trispecific antibody； [+6]

Read more
Status: Recruiting

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed/refractory hematological malignancies.

Participants needed: 10
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: The Affiliated People's Hospital of Ningbo UniversityUpdated: Sep 6, 2022Locations: 1
Eligibility criteria

Histological diagnosis of hematological malignancies (such as lymphoma, myeloma,... [+7]

History of allergy to any of the drugs involved in the protocol. [+7]

Read more